Oracle Agile PLM's countdown clock is real, and the risks aren't just theoretical. Between escalating security vulnerabilities and the pressure to scale, the cost of staying put is climbing fast.
In this session, Caroline Byrd, VP of Regulatory, Clinical and Quality at Nextern, joins Chuck Serrin, VP of Industry Marketing for MedTech at Propel, for a candid conversation about what finally tips the scale on a PLM migration decision. With Nextern planning to more than double its business over the next four years, the stakes were high: select a platform that could handle complex medical device development across the full product lifecycle, support a broad supplier and customer base, and scale without hitting a ceiling. After a rigorous evaluation of PTC Windchill, Greenlight Guru, Grand Avenue, and others, Nextern chose Propel. This session unpacks exactly why, and what it means for MedTech companies still riding out their Agile investment.








